Provided by Tiger Fintech (Singapore) Pte. Ltd.

Celcuity Inc

11.22
+0.13001.17%
Post-market: 11.220.00000.00%16:05 EDT
Volume:185.58K
Turnover:2.10M
Market Cap:424.56M
PE:-3.96
High:11.66
Open:11.04
Low:10.99
Close:11.09
Loading ...

Company Profile

Company Name:
Celcuity Inc
Exchange:
NASDAQ
Establishment Date:
2011
Employees:
87
Office Location:
16305 36th Avenue North,Suite 100,Minneapolis,Minnesota,United States
Zip Code:
55446
Fax:
- -
Introduction:
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Directors

Name
Position
Brian F. Sullivan
Chairman of the Board and Chief Executive Officer
Lance G. Laing
Director, Chief Science Officer, Vice President and Secretary
David F. Dalvey
Director
Leo T. Furcht
Director
Richard E. Buller
Director
Richard J. Nigon
Director

Shareholders

Name
Position
Brian F. Sullivan
Chairman of the Board and Chief Executive Officer
Vicky Hahne
Chief Financial Officer
Lance G. Laing
Director, Chief Science Officer, Vice President and Secretary